Pre-made Ravulizumab biosimilar ( Whole mAb, anti-C5 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-472
Anti-C5 therapeutic antibody (Pre-made Ravulizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5).
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-C5 therapeutic antibody (Pre-made Ravulizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||5i5k:HL:XY|
|95-98% SI Structure||None|
|Conditions Approved||Paroxysmal nocturnal haemoglobinuria|
|Conditions Active||Haemolytic uraemic syndrome;Myasthenia gravis;IgA nephropathy|